See more : Scape Technologies A/S (SCAPE.CO) Income Statement Analysis – Financial Results
Complete financial analysis of Tyra Biosciences, Inc. (TYRA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Tyra Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Beacon Energy plc (BCE.L) Income Statement Analysis – Financial Results
- Automatic Bank Services Limited (SHVA.TA) Income Statement Analysis – Financial Results
- Technical Communications Corporation (TCCO) Income Statement Analysis – Financial Results
- PT Industri dan Perdagangan Bintraco Dharma Tbk (CARS.JK) Income Statement Analysis – Financial Results
- Larimar Therapeutics, Inc. (LRMR) Income Statement Analysis – Financial Results
Tyra Biosciences, Inc. (TYRA)
About Tyra Biosciences, Inc.
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 353.00K | 296.00K | 140.00K | 47.00K | 8.00K |
| Gross Profit | -353.00K | -296.00K | -140.00K | -47.00K | -8.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 62.52M | 43.01M | 20.64M | 7.20M | 1.79M |
| General & Administrative | 17.43M | 15.92M | 5.65M | 2.09M | 1.33M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 17.43M | 15.92M | 5.65M | 2.09M | 1.33M |
| Other Expenses | 0.00 | -50.00K | -19.00K | -23.00K | -8.00K |
| Operating Expenses | 79.95M | 58.93M | 26.29M | 9.30M | 3.12M |
| Cost & Expenses | 79.95M | 58.93M | 26.29M | 9.30M | 3.12M |
| Interest Income | 10.85M | 3.65M | 13.00K | 1.00 | 1.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 1.00K | 1.00K |
| Depreciation & Amortization | 353.00K | 296.00K | 140.00K | 47.00K | 8.00K |
| EBITDA | -79.59M | -58.63M | -26.15M | -9.25M | -3.11M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -79.95M | -58.93M | -26.29M | -9.30M | -3.12M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 10.81M | 3.60M | -6.00K | -39.00K | -943.00K |
| Income Before Tax | -69.13M | -55.33M | -26.29M | -9.34M | -4.07M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -3.60M | -153.00K | -22.00K | -7.00K |
| Net Income | -69.13M | -51.72M | -26.14M | -9.31M | -4.06M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.62 | -1.23 | -0.63 | -0.22 | -0.10 |
| EPS Diluted | -1.62 | -1.23 | -0.63 | -0.22 | -0.10 |
| Weighted Avg Shares Out | 42.70M | 41.88M | 41.44M | 42.54M | 42.54M |
| Weighted Avg Shares Out (Dil) | 42.70M | 41.88M | 41.44M | 42.54M | 42.54M |
Post-Election Insider Buying in These 6 Stocks Is Huge
24/7 Wall St. Insights As we race toward the end of the year, the past week brought some huge insider share purchases.
Tyra Biosciences to Present at Upcoming Investor Conferences
CARLSBAD, Calif. , Nov. 13, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that company management will participate...
Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights
- Reported positive interim clinical proof-of-concept results for TYRA-300 in mUC from SURF301 Ph1/2 study - - IND cleared for Phase 2 study of TYRA-300 in pediatric achondroplasia (BEACH301) - - Strengthened leadership with appointment of Doug Warner, MD as...
Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301)
– TYRA-300 is the first oral FGFR-3 selective inhibitor to be well-tolerated in clinical studies – – First child with achondroplasia expected to be dosed in Q1 2025 – CARLSBAD, Calif. , Oct. 28, 2024 /PRNewswire/ -- Tyra Biosciences, Inc....
Why Is Cancer-Focused Tyra Biosciences Stock Falling On Friday?
On Thursday, Tyra Biosciences, Inc. TYRA released clinical proof-of-concept data for TYRA-300 in patients with metastatic urothelial (mUC) cancer from its ongoing SURF301 Phase 1/2 study.
Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC)
- Encouraging preliminary anti-tumor activity observed in heavily pre-treated population - - At ≥ 90 mg QD, 6 out of 11 (54.5%) patients with FGFR3+ mUC achieved a confirmed partial response (PR), with 100% disease control rate and sustained duration...
Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET
CARLSBAD, Calif. , Oct. 23, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that it will host...
Tyra Biosciences: Upcoming FGFR3 Inhibitor Data Is A Major Inflection Point
Tyra Biosciences will release interim data for its FGFR3-inhibitor TYRA-300 in treating urothelial carcinoma and solid tumors at ENA 2024 on October 25th. Positive interim data could advance TYRA-300 towards a phase 2 study for metastatic urothelial carcinoma and non-muscle...
BofA Upgrades Tyra Biosciences As Investors Focus On Preclinical Data Amid High Benchmarks Set By Johnson & Johnson's Drug
BofA Securities has upgraded Tyra Biosciences TYRA, a clinical-stage biotechnology company focused on developing next-generation precision medicines.
Tyra Biosciences Announces Late-Breaking Oral Presentation on Preliminary Safety and Anti-Tumor Activity of TYRA-300 from SURF301 at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024)
-TYRA will also present two posters on PK/PD of TYRA-300 and a Trials-in-Progress from SURF301 - CARLSBAD, Calif. , Oct. 11, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target...
Source: https://incomestatements.info
Category: Stock Reports